{"id":"W2952182954","doi":"10.1136/annrheumdis-2019-eular.3083","title":"FRI0171 CLINICAL RESPONSES IN PATIENTS WITH INADEQUATE RESPONSE TO BDMARDS UPON TREATMENT WITH UPADACITINIB","year":2019,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"Research Manitoba","funders":"Regeneron Pharmaceuticals; Gilead Sciences; AbbVie; Sanofi; Amgen; Pfizer; Samsung; Genentech; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Rheumatoid arthritis; Internal medicine; Placebo; Adverse effect; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008451489,0.0002532996,0.0007084316,0.0002178749,0.00004573764,0.00002361641,0.0002978653,0.00006601145,0.000158194],"category_scores_gemma":[0.001678801,0.0001288576,0.0001764376,0.0004877807,0.0001755436,0.0001021728,0.0001317765,0.0001239053,0.0001106779],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001071904,"about_ca_system_score_gemma":0.005090094,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003130913,"about_ca_topic_score_gemma":0.00005676529,"domain_scores_codex":[0.996837,0.0006968566,0.0006257626,0.0003889121,0.0009796922,0.000471753],"domain_scores_gemma":[0.9963269,0.001633081,0.000210996,0.001194393,0.000266465,0.0003681333],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2486709,0.003310008,0.6965616,0.0004888467,0.0006279203,0.00007323178,0.0008120527,0.0002365841,0.00001108177,0.00004670221,0.001186506,0.04797456],"study_design_scores_gemma":[0.02897323,0.009484907,0.9569201,0.002523616,0.0001184697,0.00000878341,0.0001886386,0.0003558559,0.0003402596,0.00004429813,0.0008519496,0.0001898198],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9948913,0.0001424819,0.000003224042,0.002635188,0.00005830228,0.001920291,0.00009621639,0.00002546492,0.0002274936],"genre_scores_gemma":[0.9974578,0.00007808726,0.0001227909,0.0004810595,0.00001439568,0.00008094914,0.00001558713,0.00004021748,0.001709086],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2603586,"threshold_uncertainty_score":0.9029608,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04816730546240868,"score_gpt":0.3694457898233973,"score_spread":0.3212784843609887,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}